RKT - Reckitt Benckiser Group plc
LSE
->
Consumer Defensive
->
Household & Personal Products
Slough,
United Kingdom
Type: Equity
RKT price evolution
RKT
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $1108.47 | $957 | $882.78 | $893.38 |
| Long term investments | ||||
| Property, plant & equipment | $598.55 | $612 | $634.68 | $659.22 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $19231.74 | $20649 | $20855.68 | $21202.28 |
| Current liabilities | ||||
| Accounts payable | $171.35 | $200 | $156.94 | $135.04 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $5669.21 | $6916 | $7309.75 | $7869.82 |
| Long term debt | $4064.45 | $4063 | $4066.77 | $4059.79 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $18606.84 | $20037 | $20264.94 | $20626.58 |
| Shareholders' equity | ||||
| Retained earnings | $284.3 | $295 | $288.52 | $281 |
| Other shareholder equity | $0.05 | $0.06 | -$0.03 | |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2054.1 | |||
| Short term investments | ||||
| Net receivables | $87.36 | $80.72 | $114.69 | $324 |
| Inventory | ||||
| Total current assets | $1354.08 | $995.9 | $2414.87 | $24941.38 |
| Long term investments | ||||
| Property, plant & equipment | $598.55 | $640.38 | $682.27 | $211.16 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $12593.22 | |||
| Total investments | ||||
| Total assets | $19231.74 | $20082.21 | $32774.89 | $37534.6 |
| Current liabilities | ||||
| Accounts payable | $171.35 | $116.33 | $271.54 | $251.96 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $5669.21 | $6415.04 | $17332.29 | $876.14 |
| Long term debt | $4064.45 | $4049.47 | $4118.99 | $21420.88 |
| Total noncurrent liabilities | $28776.31 | |||
| Total debt | ||||
| Total liabilities | $18606.84 | $19505.51 | $32109.23 | $29652.45 |
| Shareholders' equity | ||||
| Retained earnings | $284.3 | $300.39 | $378 | $207.42 |
| Other shareholder equity | $0.05 | $0.07 | $0.08 | $7391.97 |
| Total shareholder equity | ||||
| (in millions $) | 29 Jul 2021 | 30 Apr 2021 | 30 Jan 2021 | 29 Oct 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2668.75 | $4584.24 | $4697.62 | $4634.12 |
| Cost of revenue | ||||
| Gross Profit | $2668.75 | $4584.24 | $4697.62 | $4634.12 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $1608.05 | $1741.07 | $1805.19 | $1577.05 |
| Operating income | $1060.7 | $2843.17 | $2892.43 | $3057.07 |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $24.05 | $65.83 | $48.8 | $61.68 |
| Interest expense | $35.04 | $35.57 | $82.01 | $38.02 |
| Net income | ||||
| Net income | $61.12 | $123.7 | -$3321.6 | $57.9 |
| Income (for common shares) | ||||
| (in millions $) | 30 Jan 2021 | 30 Jan 2020 | 29 Oct 2014 | 29 Oct 2013 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $15735.18 | $5117.32 | $9895.1 | $9545.4 |
| Cost of revenue | ||||
| Gross Profit | $15735.18 | $5117.32 | $1933.6 | $1846.5 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $6203.52 | $4212.88 | $1079.7 | $1033.2 |
| Operating income | $9531.66 | $904.44 | $854.4 | $814.2 |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $132.38 | $7.31 | $286.5 | -$21.8 |
| Interest expense | $186.3 | $136.85 | $95.3 | $106.9 |
| Net income | ||||
| Net income | $197.95 | $479.7 | $727.3 | |
| Income (for common shares) | ||||
| (in millions $) | 29 Jul 2021 | 30 Apr 2021 | 30 Jan 2021 | 29 Oct 2020 |
|---|---|---|---|---|
| Net income | $3813.99 | $2777.34 | $9399.28 | $6558.51 |
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $2557.69 | $6273.51 | -$1677.37 | -$3661.62 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$4.95 | -$38.89 | $517.2 | $311.05 |
| Financing activities | ||||
| Dividends paid | -$3583.81 | -$2375.9 | -$1375.18 | -$6 |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$2555.19 | -$5348.48 | $1757.66 | $5465.96 |
| Effect of exchange rate | $0.8 | $0.31 | $0.89 | -$0.63 |
| Change in cash and equivalents | -$1.65 | $886.45 | $598.38 | $2114.76 |
| (in millions $) | 30 Jan 2021 | 30 Jan 2020 | 29 Oct 2014 | 29 Oct 2013 |
|---|---|---|---|---|
| Net income | $9399.28 | $897.13 | $483.8 | $732.5 |
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$1677.37 | -$6978.73 | $1151.8 | $1032.5 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $517.2 | $71.89 | -$967.4 | -$403.6 |
| Financing activities | ||||
| Dividends paid | -$1375.18 | -$101.1 | -$75.3 | |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $1757.66 | $7225.36 | -$188.1 | -$629.2 |
| Effect of exchange rate | $0.89 | $0.88 | -$0.1 | -$0.5 |
| Change in cash and equivalents | $598.38 | $319.4 | -$3.8 | -$0.8 |
News
|
Reckitt Benckiser Group PLC's Dividend Analysis
GuruFocus.com via Yahoo Finance
10 Apr 2024
|
|
An Intrinsic Calculation For Reckitt Benckiser Group plc (LON:RKT) Suggests It's 43% Undervalued
Simply Wall St. via Yahoo Finance
1 Apr 2024
|
|
Doctors urge refrigerating acne creams to reduce cancer risk
Medical Xpress
21 Mar 2024
|
|
Reckitt Chief Defends Safety of Baby Formula, Will Fight Verdict
Bloomberg
19 Mar 2024
|
|
Citi cuts Reckitt Benckiser stock PT amid $7bn drop in market capitalization By Investing.com
Investing.com
19 Mar 2024
|
|
Could Reckitt spin out baby formula wing following Enfamil crisis?
Proactive Investors
19 Mar 2024
|
|
Reckitt Is a Reminder That Consumer Health Has Risks
Bloomberg
19 Mar 2024
|
|
Reckitt will seek to overturn $60 million baby formula verdict
Reuters
16 Mar 2024
|
|
Stocks Fall as ‘Triple Witching’ Spurs Volume Jump: Markets Wrap
Bloomberg via Yahoo Finance
16 Mar 2024
|
|
Reckitt to challenge $60 mln baby formula verdict, shares sink
Reuters
16 Mar 2024
|
Fundamentals
| Market cap | $8.68T |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 1.98B |
| Revenue | $16.58B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$3.08B |
| Revenue Q/Q | -47.02% |
| Revenue Y/Y | 33.08% |
| P/E ratio | -2.82K |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 523.44 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$1.55 |
|---|---|
| ROA | -15.03% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.20 |
| Quick ratio | N/A |